Cardiovascular Devices are used in treating diseases related to the heart and the circulatory system. Renal Denervation, also known as Renal Sympathetic Denervation (RSD), is a minimally invasive, catheter-based endovascular intervention that utilizes radiofrequency energy or ultrasound energy to ablate nerves in the walls of the renal artery, causing a reduction in the nerve activity which ultimately reduces the blood pressure in patients with resistant hypertension. GlobalData uses proprietary data and analytics to provide a comprehensive report on the renal denervation catheters devices market, including market shares of different players within Switzerland. Buy the latest report here.
In 2023, GlobalData’s Market Model methodology determined that the leading player in the renal denervation catheters market in Switzerland was Abbott laboratories followed by Boston Scientific, Medtronic and ReCor Medical.
The Renal Denervation Catheter consists of Radio Frequency Renal Denervation Catheters, Ultrasound Catheters and Micro-Infusion Catheters. Radio Frequency Renal Denervation Catheters are used to deliver high frequency alternating current (in the range of 300-500 kHz) to ablate nerves in the renal artery. Ultrasound Catheters are used to deliver high frequency sound waves (i.e. , rapid mechanical oscillations) to destroy the renal nerves. Micro-Infusion Catheters are used to deliver chemical agents, such as ethanol, to denervate the renal arteries.
The value of the renal denervation catheters devices market within Switzerland was expected to be over $0.6m in 2023.
For the latest complete market share analysis of renal denervation catheters device market in Switzerland, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.